A new federal report found that Medicaid insurers have not done a good job in catching fraud or reporting it to states; Blink Health and former officials at Express Scripts have teamed up to create a venture that replaces the “complicated and opaque” pharmacy payment system; CDC is warning that people overdosing on synthetic opioids may need multiple doses of naloxone.
A new federal report found that Medicaid insurers have not done a good job in catching fraud and also neglect to report it to states when it is discovered. California Healthline reported that even when some health plans removed providers for fraud, they neglected to tell the state, which could allow those providers to defraud other insurers. In 2015, health insurers identified $57.8 million in overpayments related to fraud or abuse, and just 22% of those payments were recovered.
Blink Health and former officials at Express Scripts have teamed up to create a venture that replaces the “complicated and opaque” pharmacy payment system, including pharmacy benefit managers (PBMs). Blue Eagle Health arose after Blink, which helps patients shop for lower-cost prescription drugs through its website and mobile app, discovered that CVS Health Corp and Walgreens Boots Alliance stopped filling prescriptions through Blink’s site, according to Bloomberg. Blue Eagle has a network of more than 33,000 pharmacies and is processing prescription purchases for only Blink as of now. It will eventually take on other clients.
There has been an increased supply of illicitly manufactured fentanyl and fentanyl analogues, which are driving opioid overdose deaths—synthetic opioids account for more than half. According to NBC News, the CDC is warning that people who overdose on these new synthetic opioids may need multiple doses of naloxone. Emergency responders and physicians will need to be aware that someone overdosing on a synthetic may need extra care due to the toxicity being reported.
Exploring Medicare Advantage Prior Authorization Variations
March 26th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the March 2024 issue of The American Journal of Managed Care® about their findings on variations in prior authorization use across Medicare Advantage plans.
Listen
Navigating Health Literacy, Social Determinants, and Discrimination in National Health Plans
February 13th 2024On this episode of Managed Care Cast, we're talking with the authors of a study published in the February 2024 issue of The American Journal of Managed Care® about their findings on how health plans can screen for health literacy, social determinants of health, and perceived health care discrimination.
Listen
FDA Approves Vadadustat for Anemia in Patients With CKD Undergoing Dialysis
March 28th 2024The FDA approved vadadustat (Vafseo), an oral medication, to treat anemia in adult patients with chronic kidney disease (CKD) on dialysis for at least 3 months. This fills a need for a new treatment option as anemia is common in these patients and can significantly impact their quality of life.
Read More
Risk for Second Primary Melanoma Increases After Primary Melanoma Diagnosis as Men Age
March 28th 2024A population-based cohort study out of Norway has found that older men have a higher risk of developing second primary invasive melanoma following an initial primary melanoma, suggesting the benefits of increased surveillance in these patients.
Read More